Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Blum Holdings, Inc. (BLMH)
USD0.19
-0.03 (-13.64%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
3242 South Halladay Street 92705
Downey, CA, US
Downey, CA, US
CEO
Sabas Carrillo
Website
blumholdings.com
IPO
2012-05-10
CIK 1996210 ISIN US09642F1012
Description
Blum Holdings, Inc. is an entity operating within California's regulated cannabis market, comprehensively addressing both medical and adult-use demands. The company's multifaceted involvement encompasses the cultivation, production, distribution, and retail sales of cannabis products. Its business activities are organized into two primary divisions: Cannabis Retail and Cannabis Distribution. This includes direct oversight of its cultivation sites, manufacturing facilities, and dispensaries catering to diverse customer needs. The company, originally established in 2010, maintains its principal office in Santa Ana, California. It adopted the name Blum Holdings, Inc. in January 2024, having previously operated as Unrivaled Brands, Inc.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.19
-0.03 (-13.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6.9K
Beta
2.14
Float Shares
4.52M
Free Float %
33.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.42% | -14.78% | +31.53% | -3.88% | -63.40% | -59.03% | -59.82% | +1,149.50% | +8.65% | -95.37% | -98.55% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.19
Quality scores
Altman Z-Score
-14.22
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+14.8% ★ Q1'26: +56.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-124.3% Q1'26: -53.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-37.7% Q1'26: -6.0% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-49.4% Q1'26: -33.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%— Q1'26: +180.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q1'26: +156.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-1.19× Q1'26: -2.17× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 1/5 | 5/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-4.43M
OE per share TTM
-0.35
Owner's Yield
-56.17%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
61.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
10
Sells
0
Shares acquired
3.9K
Shares disposed
—
Cash buys
10.00
Cash sales
—
Net activity
+3,910
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | ROSENBERG DOUGLAS | 10% Owner | M-Exempt | A | Common Stock | 3,238,547 | 0.98 | 3.17M | 3,238,547 | D | ↗ |
| 2025-12-31 | Miller James | Director | A-Award | A | Common Stock | 191,327 | 0.98 | 187.5K | 191,327 | D | ↗ |
| 2025-12-31 | HIRSCH BRADLEY LAURENCE | Director | A-Award | A | Common Stock | 64,082 | 0.98 | 62.8K | 64,082 | D | ↗ |
| 2025-12-31 | Chan Patty | Officer | A-Award | A | Common Stock | 30,612 | 0.98 | 30.0K | 30,612 | D | ↗ |
| 2025-12-31 | Carrillo Sabas D | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,551,020 | 0.98 | 2.50M | 11,496,094 | I | ↗ |
| 2025-12-31 | Barron Matthew T | Director | A-Award | A | Common Stock | 194,183 | 0.98 | 190.3K | 194,183 | D | ↗ |
| 2025-12-05 | ROSENBERG DOUGLAS | 10% Owner | — | — | Warrants to Purchase Common Stock | 571,429 | 0.35 | 200.0K | 0 | D | ↗ |
| 2025-11-13 | Carrillo Sabas D | Director / Officer / 10% Owner | J-Other | A | Common Stock | 2,482,308 | 0.98 | 2.43M | 8,945,074 | I | ↗ |
| 2025-05-30 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 192 | 0.70 | 134.40 | 92,389 | D | ↗ |
| 2025-05-29 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 400 | 0.70 | 280.00 | 91,697 | D | ↗ |
| 2025-05-28 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 250 | 0.76 | 190.00 | 91,297 | D | ↗ |
| 2025-05-23 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 250 | 0.72 | 180.00 | 91,047 | D | ↗ |
| 2025-05-21 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 100 | 0.80 | 80.00 | 90,497 | D | ↗ |
| 2025-05-20 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 420 | 0.84 | 352.80 | 90,397 | D | ↗ |
| 2025-05-19 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,170 | 0.84 | 982.80 | 89,457 | D | ↗ |
| 2025-05-08 | ROSENBERG DOUGLAS | 10% Owner | — | — | Warrants to Purchase Common Stock | 122,642 | 0.53 | 65.0K | 0 | D | ↗ |
| 2025-05-08 | HIRSCH BRADLEY LAURENCE | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Carrillo Sabas D | Director / Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 87,787 | D | ↗ |
| 2024-12-30 | ROSENBERG DOUGLAS | 10% Owner | — | — | Warrants to Purchase Common Stock | 117,647 | 0.17 | 20.0K | 0 | D | ↗ |
| 2024-12-30 | Miller James | Director | D-Return | D | Warrants to Purchase Common Stock | 17,857 | 2.80 | 50.0K | 0 | D | ↗ |
| 2024-12-30 | Chan Patty | Officer | J-Other | A | Series V Preferred Stock | 0 | 0.00 | — | 714,286 | D | ↗ |
| 2024-12-30 | Carrillo Sabas D | Director / Officer / 10% Owner | J-Other | A | Series V Preferred Stock | 0 | 0.00 | — | 3,571,429 | I | ↗ |
| 2024-12-30 | Barron Matthew T | Director | J-Other | A | Series V Preferred Stock | 0 | 0.00 | — | 71,429 | D | ↗ |
| 2024-12-17 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 200 | 0.54 | 108.00 | 87,787 | D | ↗ |
| 2024-12-13 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 200 | 0.48 | 96.00 | 87,387 | D | ↗ |
| 2024-12-12 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 280 | 0.48 | 134.40 | 86,712 | D | ↗ |
| 2024-12-11 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 250 | 0.50 | 125.00 | 85,307 | D | ↗ |
| 2024-12-10 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 0.48 | 240.00 | 83,657 | D | ↗ |
| 2024-12-05 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 0.49 | 1.2K | 82,107 | D | ↗ |
| 2024-12-04 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 0.48 | 1.2K | 79,607 | D | ↗ |
| 2024-12-03 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 0.38 | 950.00 | 72,107 | D | ↗ |
| 2024-11-27 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 0.38 | 950.00 | 67,107 | D | ↗ |
| 2024-11-26 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 0.43 | 1.1K | 62,107 | D | ↗ |
| 2024-11-21 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 15,000 | 0.16 | 2.4K | 47,737 | D | ↗ |
| 2024-11-20 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.18 | 1.8K | 27,737 | D | ↗ |
| 2024-11-19 | Carrillo Sabas D | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 12,737 | 0.18 | 2.3K | 17,737 | D | ↗ |
Executive team
Top executives
EBIT / Employee
-193.9K
Shares Outstanding
13.55M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Joe Gerlach | Chief Cannabis Officer & Director for Korova | — | — |
| Patty Chan | Chief Financial Officer | — | female |
| Robert Baca | Chief Legal Officer & Secretary | — | male |
| Sabas Carrillo | Chairman & Chief Executive Officer | — | male |
| Tracy McCourt | Chief Revenue Officer | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BLMH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
